Jiangsu Vcare Secures New Round of Financing Totaling CNY 100 Million​

　　Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) secures another strategic investment of CNY 100 million. This round was jointly invested by Nanjing NII Group, Renpu Capital, and Nanjing Innovation Capital Group. The funds will primarily be used to advance the clinical research of innovative drug pipeline projects like Vicagrel and VC004, while accelerating strategic layout in the CDMO business sector.

　　Jiangsu Vcare, established in 2010 and located in the Nanjing Biotech and Pharmaceutical Valley, is a high-tech pharmaceutical company focused on the R&D, services, and innovation across the entire chemical drug industry chain. After over a decade of development, the company now employs over 300 staff, with master's and PhD holders comprising more than 50% of its R&D team. It has built its own high-end drug R&D center spanning over 20,000 sqm, featuring well-equipped laboratories for synthesis, analysis, formulation, cell biology, and enzyme activity testing, alongside experienced teams in medicinal chemistry, pharmacology, and clinical development.

　　Addressing unmet clinical needs in therapeutic areas such as cardiovascular and cerebrovascular diseases, oncology, autoimmune disorders, and inflammation, the company leverages its extensive drug development experience to create highly competitive innovative products through independent R&D and collaborative innovation. Its first innovative drug, Vicagrel, has been recognized as "one of the most commercially promising projects in its therapeutic field." It has completed Phase II clinical trials in China. Preparations for the initiation of the Phase I clinical trial of Vicagrel in the United States under the 505(B)2 pathway have been finalized,while its Phase III trials in China is expected to commence in the fourth quarter of this year. Its second-generation drug-resistant TRK inhibitor has completed Phase Ia dose-escalation trials, demonstrating favorable in vivo PK properties. In the Phase Ib expansion study involving NTRK-positive patients, some have achieved partial response (PR) with significant shrinkage of tumor lesions. The highly selective JAK1 inhibitor has completed IND submission. The subsequent R&D pipeline is robust, including multiple First-in-class and Best-in-class projects under development.

　　Over the past decade, Jiangsu Vcare has steadily advanced its innovative drug programs while experiencing rapid growth in its external service business of CRO/CDMO. With the support of its investors, the company is poised to accelerate the clinical research of its innovative drugs, bringing more and better innovative therapeutics to patients worldwide. In the next decade, we will strive to elevate the company's comprehensive capabilities in chemical drug R&D to an advanced domestic level, benefiting more patients.

　　Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We are deeply honored to receive the strong trust and tremendous support from three outstanding investment institutions in this financing round. This funding will play a crucial role in comprehensively and rapidly advancing the layout of our CDMO business, propelling the Phase III clinical research of our innovative drug Vicagrel, enriching our product pipeline, and further strengthening our leading position in the field of integrated ' Chemistry + Pharmacy + Medicine' R&D services across the entire chemical drug industry chain. We will remain true to our founding mission, steadfastly upholding our philosophy of providing one-stop, full-process drug R&D services to benefit more patients. We will continue to focus on independent innovation and open collaboration to unlock greater potential."